Raltegravir is the first HIV integrase inhibitor available in clinical practice for the treatment of HIV-infection in both naive and experienced patients. Randomized clinical trials have evidenced a good safety profile. However, grade III-IV creatine phosphokinase increases have been more frequently observed in patients receiving raltegravir in respect of comparator treatments and cases of rhabdomyolysis has been reported in the literature. In this article, we give an insight into the available data from clinical studies and case reports and possible pathogenetic mechanisms of raltegravir-related muscle toxicity.
Keywords: Raltegravir; Myalgia; Creatine phosphokinase; HAART
Articolo presente in – HAART and correlated pathologies n. 10 –